Targeting exhausted cytotoxic T cells through CTLA-4 inhibition promotes elimination of neoplastic cells in human myelofibrosis xenografts
- PMID: 38953347
- DOI: 10.1002/ajh.27428
Targeting exhausted cytotoxic T cells through CTLA-4 inhibition promotes elimination of neoplastic cells in human myelofibrosis xenografts
Abstract
Myeloproliferative neoplasms represent a group of clonal hematopoietic disorders of which myelofibrosis (MF) is the most aggressive. In the context of myeloid neoplasms, there is a growing recognition of the dysregulation of immune response and T-cell function as significant contributors to disease progression and immune evasion. We investigated cytotoxic T-cell exhaustion in MF to restore immune response against malignant cells. Increased expression of inhibitory receptors like CTLA-4 was observed on cytotoxic T cells from MF patients together with a reduced secretion of IFNɣ and TNFɑ. CTLA-4 ligands CD80 and CD86 were increased on MF granulocytes and monocytes highlighting a possible role for myeloid cells in suppressing T-cell activation in MF patients. Unlike healthy donors, the activation of cytotoxic T cells from MF patients was attenuated in the presence of myeloid cells and restored when T cells were cultured alone or treated with anti-CTLA-4. Moreover, anti-CTLA-4 treatment promoted elimination of neoplastic monocytes and granulocytes in a co-culture system with cytotoxic T cells. To test CTLA-4 inhibition in vivo, patient-derived xenografts were generated by transplanting MF CD34+ cells and by infusing homologous T cells in NSGS mice. CTLA-4 blockade reduced human myeloid chimerism and led to T-cell expansion in spleen and bone marrow. Overall, these findings shed light on T-cell dysfunction in MF and suggest that CTLA-4 blockade can boost the cytotoxic T cell-mediated immune response against tumor cells.
© 2024 The Author(s). American Journal of Hematology published by Wiley Periodicals LLC.
References
REFERENCES
-
- Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292‐2302.
-
- Spivak JL. Myeloproliferative neoplasms. N Engl J Med. 2017;376:2168‐2181.
-
- Rontauroli S, Carretta C, Parenti S, Bertesi M, Manfredini R. Novel molecular insights into leukemic evolution of myeloproliferative neoplasms: a single cell perspective. Int J Mol Sci. 2022;23(23):15256.
-
- Tefferi A. Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management. Am J Hematol. 2023;98(5):801‐821.
-
- Holmström MO, Hasselbalch HC, Andersen MH. Cancer immune therapy for Philadelphia chromosome‐negative chronic myeloproliferative neoplasms. Cancers (Basel). 2020;12(7):1‐21.